Lecanemab

← Pipeline

Lecanemab

Eisai / Biogen · Alzheimer's disease
Approved / Late-stage active active, not recruiting CT.gov grounded

Anti-amyloid antibody program targeting plaque clearance in early Alzheimer's disease.

Open Alzheimer's disease hub Filter main pipeline

Program overview

Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Phase
Approved / Late-stage
Status
active
Recruitment
active, not recruiting
Confidence
high
Watch priority
1
Last verified
20 Apr 2026

Sponsor and trial identifiers

Sponsor
Eisai / Biogen
Trial IDs
NCT03887455
ClinicalTrials.gov exact matches: NCT03887455

Regions and recruitment

Active in 14 regions
United States Australia Canada China France Germany Italy Japan Russia Singapore South Korea Spain Sweden United Kingdom

Indication tags

Alzheimer's early Alzheimer's

Milestones and catalysts

Last milestone
Global rollout continues after regulatory approvals in multiple markets.
Next expected catalyst
Additional post-approval data and uptake signals.

Related pages

Disease hub Alzheimer's disease hub Disease-specific views with programs, mechanisms, and related context.
Research Research agenda Research notes and background around Alzheimer's disease.
Key Targets Key targets The mechanisms and intervention levers behind these programs.
Discover Discover Explainers and visual introductions to the science behind neurodegeneration.
Join Get involved Contribute research, writing, design, engineering, or review.

Related programs

Each card explains why it is here so you can read the overlap at a glance.

Priority 1
Approved / Late-stage active active, not recruiting

Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.

Shown because it shares same disease bench and same mechanism with Lecanemab.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Further rollout, label evolution, and follow-up data.
Last verified
20 Apr 2026
Priority 2
Mid / Late-stage active active, not recruiting

Follow-on anti-amyloid program that could matter for the next wave of Alzheimer's competition.

Shown because it shares same disease bench and same mechanism with Lecanemab.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Recruitment updates and larger efficacy or safety read-throughs.
Last verified
20 Apr 2026
Priority 2
Mid-stage active active, not recruiting

A serious tau program that matters because the Alzheimer's field still needs credible combination therapy attempts.

Shown because it shares same disease bench and same modality with Lecanemab.
Mechanism
anti-MTBR tau antibody
Modality
monoclonal antibody
Next catalyst
Whether the tau-plus-amyloid combination thesis produces a clearer signal than monotherapy tracks.
Last verified
20 Apr 2026
Priority 2
Late-stage active active, not recruiting

A precision-style Alzheimer's program built around APOE4 biology rather than a broad undifferentiated patient pool.

Shown because it shares same disease bench and shared biology: alzheimer's with Lecanemab.
Mechanism
anti-amyloid oligomer modulation
Modality
small molecule
Next catalyst
Long-term extension updates and any signal on APOE4-enriched positioning.
Last verified
20 Apr 2026

Source links

ClinicalTrials.gov NCT03887455 ClinicalTrials.gov search LEQEMBI
Scroll to Top